nmCRPC VL

Phase III ARAMIS Trial Darolutamide in Patients with Non-metastatic Castration-resistant Prostate Cancer Meets Primary Endpoint - Tom Keane

Details
(Length of video: 5 min) Tom Keane, MBBCh, FRCSI, FACS provides highlights of the recent press release of ARAMIS, a phase III trial of darolutamide in patients with non-metastatic castrate-resistant prostate cancer. Darolutamide significantly extended metastasis-free survival compared to placebo, meeting its primary endpoint. The safety profile and tolerability of darolutamide observed in the ARAM...

Combination Therapies and Quality of Life Data in Prostate Cancer - Fred Saad

Details
Charles Ryan and Fred Saad discuss the data results in patients with mCRPC from a combined therapeutic approach with abiraterone and apalutamide. They discuss the rationale and theory behind these results. They move to discuss the quality of life analysis for patients with CRPC. A review of the SPARTAN trial and the optimistic results from his work. Biographies: Fred Saad MD FRCS is a full-time pr...

nmCRPC Patient Population - Discussion with Charles Ryan and Alicia Morgans

Details
Charles Ryan and Alicia Morgans discuss the M0 patient population and what is the meaning of the term "nonmetastatic" prostate cancer. They highlight the relevance of meaningful dialogue that should be had with patients to assure the right treatment choice is made. Biographies: Charles J. Ryan, MD Alicia Morgans, MD, MPH

The PROSPER Trial: Chemotherapy-Related Endpoints in Patients with nmCRPC - Neal Shore

Details
(Length of Presentation: 9 min) Neal Shore, MD, FACS shares his 2018 AUA presentation on the groundbreaking PROSPER trial: chemotherapy-related endpoints in patients with nonmetastatic castration-resistant prostate cancer treated with enzalutamide. Meeting an unmet need in this Index 1 patient population with a goal of delaying time to metastasis has the potential to delay cancer-related morbidity...

AUA Castration-Resistant Prostate Cancer Guidelines - Interview with Michael Cookson

Details
(Length of Discussion: 10 min) Michael Cookson, MD, MMHC, talks with Alicia Morgans, MD on the newest developments in the AUA CRPC guidelines incorporating the results of the SPARTAN and PROSPER nmCRPC studies. The intent of this guideline amendment is to update current management of index patient 1: asymptomatic non-metastatic CRPC. Michael shares the need to revamp current guidelines which are s...

The Incredible Shrinking nmCRPC - Phillip Koo

Details
(Length of Presentation: 12 min) Phillip Koo, MD presents the impact of advanced imaging in prostate cancer and his imaging strategy for the M0 CRPC patient. His discussion is shaped around the impact next-generation imaging has had on prostate cancer and M0 CRPC with the approvals of Axumin PET/CT, PSMA PET/CT, and Choline PET/CT, and improving the image quality compared to CT and Bone Scan. He d...

The Implications of the SPARTAN Trial in the treatment of nmCRPC in Clinical Practice - Conversation with Eric Small

Details
(Length of Discussion: 23 min) Eric Small discusses (SPARTAN), the Study of Apalutamide in Men With Non-Metastatic Castration-Resistant Prostate Cancer with Alicia Morgans. He reviews the trial and the practical clinical practice questions that the data raises. He details the logic behind the development of the study and the unmet need for this patient population. Other key points discussed includ...

First presentation of SPARTAN - a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) - Eric Small

Details
(Length of Presentation: 23 min) The first presentation of a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC), called SPARTAN is provided here. Eric Small presents the SPARTAN trial first data analysis including the background, methods, primary end points, time to metastasis, progress...

nmCRPC Outcomes in the Use of New Androgen Receptor Targeted Therapies - A Conversation with Charles Ryan and Alicia Morgans

Details
(Length of Conversation: 24 min) Alicia Morgans and Charles Ryan discuss data that was presented at the ASCO GU 2018 meeting including two phase III trials, Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer ( SPARTAN ) and Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer ( PROSPER ) and the advances fo...

nmCRPC - Early Treatment Leading to Favorable Outcomes - Fred Saad.

Details
(Length of Discussion: 16 min) Fred Saad and Alicia Morgans discuss results from A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN) and Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (PROSPER), as well as the endpoint of metastases free survival (MFS). It is exciting that early tr...